Sai Parenteral'S IPO Overview
Sai Parenteral'S IPO IPO is a Mainboard public issue offered through a Book Building issue with a total issue size of ₹TBA crores. The IPO price band is set at ₹TBA per share, and retail investors can apply with a minimum investment of ₹— as per IPO guidelines.
The Sai Parenteral'S IPO IPO opens on 24 Mar 2026 and closes on 27 Mar 2026. The IPO allotment is expected to be finalized on 30 Mar 2026, and the equity shares are proposed to be listed on BSE,NSE on 2 Apr 2026.
Investors can refer to the Sai Parenteral'S IPO IPO RHP-DRHP for detailed information. The issue is managed by Arihant Capital Markets Ltd. as the book running lead manager, while Bigshare Services Pvt Ltd is the registrar to the IPO. Before investing, market participants often review IPO details, valuation, PE ratio, financials, and risk factors.
About Sai Parenteral'S IPO
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Competitive Strength:
Diversified generic formulations player with an established track record.
Strategically located and accredited Manufacturing Facilities.
Strong focus on CDMO business.
Well-established distribution network in India and overseas.
Track record of value-accretive acquisitions.
Experienced Promoters and Senior Management with extensive domain knowledge.
Sai Parenteral'S IPO Investment Objective
Establishment of a new R&D Centre;
Repayment / prepayment of certain outstanding borrowings
Working capital requirements
Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and
General corporate purposes
Total